Join
Live feed
·
PRReleasevia Quantisnow
Alzamend Neuro Inc. logo

Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital

ByQuantisnow·Wall Street's wire, on your screen.
ALZN· Alzamend Neuro Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALZN (Alzamend Neuro Inc.) and more on Quantisnow.